Rossari Biotech Limited's Board of Directors convened on January 17, 2026, approving the unaudited financial results for the quarter and nine months ended December 31, 2025. The company also granted in-principle approval for its wholly-owned subsidiary, Rossari International Limited, to establish greenfield specialty chemicals manufacturing facilities in the Kingdom of Saudi Arabia (KSA). This strategic move aims to enhance supply capabilities, accelerate market entry, and strengthen Rossari's position in the specialty chemicals sector, with funding expected through a mix of equity, debt, and internal accruals.

Further, the Board approved the allotment of 2,000 equity shares under the Rossari Employee Stock Option Plan - 2019, increasing the company's issued and paid-up equity share capital. In a separate decision, the Board approved the sale of an office premises located in Kanjurmarg, Mumbai, for ₹25 Crores to Bhagwati Grand Celebration LLP, a transaction not expected to impact business operations. Additionally, the closure of Rossari Bangladesh Limited, a wholly-owned subsidiary, was approved, subject to regulatory clearance, and is not anticipated to affect the company's operations.

The company also reported its financial performance for the period. For the quarter ended December 31, 2025, consolidated revenue from operations stood at ₹5,816.80 million, with a profit after tax of ₹327.74 million. Standalone revenue from operations was ₹4,506.58 million, and profit after tax was ₹306.26 million. For the nine months ended December 31, 2025, consolidated revenue was ₹17,115.03 million, and profit after tax was ₹1,032.46 million. Standalone revenue for the nine months was ₹12,359.28 million, with a profit after tax of ₹881.08 million.